ALS Clinical Trials | ALS Therapy Development Institute

Your participation in an ALS clinical trial provides researchers with the data they need to determine whether or not a potential treatment is safe and effective, and ultimately, whether or not it should be available as a medication to all those with ALS. The ALS Therapy Development Institute is unbiased in our listing of clinical trials and provides information on all those enrolling worldwide.

We encourage you to browse trials below and subscribe to our clinical trials email to receive monthly updates with changes to trials listed in this database.

Currently Enrolling Clinical Trials

List includes only interventional trials with locations in the US.

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Phase 3 - Recruiting

Enrollment: 380

Drug: Unknown

Type: Interventional

Open Label: Unknown

Countries: CA, Germany, Italy, Japan, Other, Switzerland, US

Learn More

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 24

Drug: Unknown

Type: Interventional

Open Label: No

Countries: CA, France, US

Learn More

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - By Invitation

Enrollment: 100

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 3 - Recruiting

Enrollment: 140

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: CA, France, Germany, Italy, Japan, US

Learn More

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Phase 2 - Recruiting

Enrollment: 18

Drug: Single group assignment

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

HEALEY ALS Platform Trial - Master Protocol

Phase 2/ 3 - Recruiting

Enrollment: 640

Drug: Multiple

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)

Phase 2 - Recruiting

Enrollment: 90

Drug: Orally available by tablet

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 228

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, France, Germany, Italy, Other, Poland, Spain, US

Learn More

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Phase 2/ 3 - Recruiting

Enrollment: 230

Drug: Drug

Type: Interventional

Open Label: Yes

Countries: CA, US

Learn More

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Phase 3 - Recruiting

Enrollment: 64

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: CA, US

Learn More

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Phase 2 - Recruiting

Enrollment: 18

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US

Learn More

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 60

Drug: Stem cells: Autologous Adipose-derived Mesenchymal Stromal Cells

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Phase 2 - Recruiting

Enrollment: 20

Drug: Open label extension

Type: Interventional

Open Label: Yes

Countries: Finland, Sweden, US

Learn More

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 50

Drug: Drug: L-Serine

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Phase 2 - Recruiting

Enrollment: 20

Drug: Drug: Ranolazine

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Phase 3 - Recruiting

Enrollment: 495

Drug: Drug - oral

Type: Interventional

Open Label: No

Countries: Germany, US

Learn More

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Phase 3 - Recruiting

Enrollment: 150

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, Brazil, CA, France, Germany, Italy, Japan, Other, Poland, Russian Federation, Spain, Sweden, United Kingdom, US

Learn More

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3 - Recruiting

Enrollment: 555

Drug: Unknown

Type: Interventional

Open Label: No

Countries: CA, US

Learn More

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase 2 - Recruiting

Enrollment: 45

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US

Learn More

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Phase 3 - Recruiting

Enrollment: 380

Drug: Unknown

Type: Interventional

Open Label: Unknown

Countries: CA, Germany, Italy, Japan, Other, Switzerland, US

Learn More

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 24

Drug: Unknown

Type: Interventional

Open Label: No

Countries: CA, France, US

Learn More

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - By Invitation

Enrollment: 100

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 3 - Recruiting

Enrollment: 140

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: CA, France, Germany, Italy, Japan, US

Learn More

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Phase 2 - Recruiting

Enrollment: 18

Drug: Single group assignment

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

HEALEY ALS Platform Trial - Master Protocol

Phase 2/ 3 - Recruiting

Enrollment: 640

Drug: Multiple

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)

Phase 2 - Recruiting

Enrollment: 90

Drug: Orally available by tablet

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 228

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, France, Germany, Italy, Other, Poland, Spain, US

Learn More

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Phase 2/ 3 - Recruiting

Enrollment: 230

Drug: Drug

Type: Interventional

Open Label: Yes

Countries: CA, US

Learn More

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Phase 3 - Recruiting

Enrollment: 64

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: CA, US

Learn More

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Phase 2 - Recruiting

Enrollment: 18

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US

Learn More

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 60

Drug: Stem cells: Autologous Adipose-derived Mesenchymal Stromal Cells

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Phase 2 - Recruiting

Enrollment: 20

Drug: Open label extension

Type: Interventional

Open Label: Yes

Countries: Finland, Sweden, US

Learn More

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2 - Recruiting

Enrollment: 50

Drug: Drug: L-Serine

Type: Interventional

Open Label: Unknown

Countries: US

Learn More

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Phase 2 - Recruiting

Enrollment: 20

Drug: Drug: Ranolazine

Type: Interventional

Open Label: Yes

Countries: US

Learn More

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Phase 3 - Recruiting

Enrollment: 495

Drug: Drug - oral

Type: Interventional

Open Label: No

Countries: Germany, US

Learn More

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Phase 3 - Recruiting

Enrollment: 150

Drug: Unknown

Type: Interventional

Open Label: Yes

Countries: Australia, Belgium, Brazil, CA, France, Germany, Italy, Japan, Other, Poland, Russian Federation, Spain, Sweden, United Kingdom, US

Learn More

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3 - Recruiting

Enrollment: 555

Drug: Unknown

Type: Interventional

Open Label: No

Countries: CA, US

Learn More

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase 2 - Recruiting

Enrollment: 45

Drug: Unknown

Type: Interventional

Open Label: No

Countries: US

Learn More

Have additional questions? Speak to someone at ALS TDI.

Search All Active Clinical Trials

Not sure where to begin your search? Here are some resources that you may find helpful:

Show Completed

Duration

Location(s)

No Clinical Trials found matching the supplied criteria.

{{t.Grouping}}

Last Updated: {{t.LastModified}}

Trial: {{t.Name}}

Sponsor: {{t.Sponsor}}

Treatment: {{t.TreatmentType}}

Recruitment State: {{t.Status}}

Enrollment: {{t.EstimatedEnrollment}}

Phase: {{t.Phase}}

Genetic Target: {{t.GeneticTarget}}

Duration: {{t.Duration}}

Administration: {{t.Administration}}

Open Label: {{t.OpenLabel}}

Locations:
{{l}} View all {{t.LocationCount}}

Articles About Clinical Trials

Wednesday, August 19, 2020

Do Next?